![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » HIV DRUG COMMENCES DOSING IN PHASE II TRIAL
HIV DRUG COMMENCES DOSING IN PHASE II TRIAL
July 18, 2005
Samaritan Pharmaceuticals announced that it has begun the Phase II monotherapy trial of its lead "oral entry inhibitor" antiviral agent SP01A in HIV-infected patients. Researchers hope that the trial will assure a novel mechanism of action for the treatment of HIV-infected patients.
The trial is a multicenter, double-blind, randomized, placebo-controlled, study of orally administered SP01A as treatment of HIV-infected patients. The trial is designed to accrue treatment-experienced HIV patients that are failing on their current antiviral therapy. Patients are entered into a four-week wash-out phase followed by 10 days of monotherapy treatment with SP01A. The primary analysis for the study is the reduction in viral load in each of the SP01A active and placebo arms, as measured from baseline to the study's completion.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct